Are you Dr. Ahmed?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-794-4902
Summary
- Dr. Sairah Ahmed, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Arizona. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of ConnecticutResidency, Internal Medicine, 2003 - 2006
Khyber Medical CollegeClass of 2000
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2011 - 2027
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) Start of enrollment: 2015 May 22
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Start of enrollment: 2021 Sep 08
Publications & Presentations
PubMed
- Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin's Lymphoma: A Prospective Observational ...Monica George, Khalis Mustafayev, Sairah Ahmed, Sheeba K Thomas, Ying Jiang
Hematological Oncology. 2025-03-01 - Phase II trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.Dai Chihara, Raphael E Steiner, Ranjit Nair, Lei Feng, Sairah Ahmed
Blood Advances. 2025-02-05 - Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel.Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sarah Nikiforow, Sairah Ahmed
Blood Advances. 2025-01-30
Press Mentions
Need CAR T Cell Therapy? Here’s What to ExpectJanuary 20th, 2023- What Are the New Weight Loss Drugs Everyone Is Talking About & What’s the Connection Between Weight and Cancer?January 15th, 2023
- Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin LymphomaDecember 13th, 2022
- Join now to see all
